Table 1.

Current HGF/cMET Target Therapies in Phase II/III clinical trials. To date, multiple therapies targeting the HGF/cMET pathway are showing promising results in median progression free survival when applied to a diverse range of neoplastic pathologies supporting further exploration of HGF as a potent medical therapy avenue yet to be fully exploited.

Category	Drug Name	Trial Phase	Target Neoplasm	Median Progression Free Survival	Side Effects	Conclusions	Source
HGF/SF Mab	AMG102 (Rilotumumab) +Bevacizumab	II	Renal cell carcinoma	3.7 months at 10 mg/kg and 2 months at 20 mg/kg	Edema (45.9%)	AMG102 is tolerated, but not definitively growth inhibitory	Schoffski et al. [104]
					Fatigue (37.7%)
					Nausea(27.9%)
HGF/SF Mab	AMG 102 (Rilotumumab) vs. AMG 102 after previous Bevacizumab Therapy	II	Recurrent Glioblastoma	[AMG102 only] 4.1 weeks vs. [previous Bevacizumab] 4.3 weeks	Fatigue (38%),	AMG 102 monotherapy not associated with statistically significant anti-tumor activity	Wen et al. [105]
					Headache (33%)
					Peripheral Edema (23%).
HGF/SF Mab	AMG 102 (Rilotumumab) plus mitoxantrone and prednisone	II	Castration Resistant Prostate Cancer	3.0 months [AMG 102] vs. 2.9 months [control]	Pulmonary Embolism (6%)	Addition of AMG 102 showed no efficacy improvements	Ryan et al. [106]
					Fatigue (3%)
Met Kinase Inhibitor	Tivantinib plus Erlotinib versus Placebo plus Erlotinib	III	Nonsquamous, Non-Small-Cell Lung Cancer	3.8 months [Erlotinib + Tivantinib] vs. 2.3 months for Erlotinib+Placebo	Rash	Addition of Tivantinib showed a significant delay in metastasis when compared to Erlotinib alone	Scagliotti et al. [107]
					Diarrhea
					Fatigue
					Vomiting
					Dyspnea
Met Kinase Inhibitor	Tivantinib vs. Placebo	II	Hepatocellular Carcinoma	1–6 months [Titantivib] vs. 1–4 months [Placebo]	Neutropenia (14%)	Beneficial second line treatment for c-MET-high advanced HCC.	Santoro et al. [108]
					Anemia (11%)
Met Kinase Inhibitor	Tivantinib	II	Microphthalmia transcription factor (MITF)-associated (MiT) tumors	3.6 months [overall] vs. 5.5 months [ASPS] vs. 1.9 months [CCS and tRCC]	Anemia (4%)	Safe and tolerable at doses of 360mg BID, with moderate antitumor response	Wagner et al. [109]
					Neutropenia (4%).
					Thrombocytopenia
					Deep vein thrombosis (6.4%)
Met Kinase Inhibitor	PF-02341066 (Crizotinib) vs. Pemetrexed or Docetaxel	III	ALK+ Non-Small Cell Lung Cancer	7.7 months [crizotinib] vs. 3.0 months [control]	Visual disorder	Crizotinib is superior to standard chemotherapy in terms of progression free survival, symptomology, and quality of life	Shaw et al. [110]
					GI SE
					Elevated liver aminotransferase levels
Met Kinase Inhibitor	Cabozantinib	III	Medullary Thyroid Carcinoma	11.2 months [cabozantinib] vs. 4.0 months [placebo]	Diarrhea	Cabozantinib resulted in statistically significant increased progression free survival length of time.	Elisei et al. [111]
					Palmar-plantar erythrodysesthesia Decreased weight and appetite Nausea
					Fatigue
Met Kinase Inhibitor	Foretinib	II	Papillary Renal Cell Carcinoma	9.3 months [Foretinib] vs. 1.3 months [Sunitinib]	Fatigue, Hypertension, Gastrointestinal toxicities	Foretinib demonstrated a high response rate in cancers with known germline MET mutations	Choueiri et al. [112]
					Pulmonary Emboli.
Met Kinase Inhibitor	Foretinib	II	Gastric Cancer	1.7 months vs. [no comparison]	Hypertension (35%)	Foretinib is an insufficient monotherapy in the treatment of gastric cancer	Shah et al. [113]
					Elevated Aspartate Aminotransferase (23%)